Evidence · Randomised trial
Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial.
- Enteral feeding
- Medical
- Necrotising enterocolitis
- Nursing
- Nutrition and gastrointestinal
This paper is from 2014, more than five years ago. Newer evidence may have been published since.
Summary
Randomised double-blind placebo-controlled trial of Bifidobacterium breve M-16V supplementation in preterm neonates, registered in Australia and New Zealand. It included independent assessment of product quality, including strain identity, viability over shelf-life and absence of contamination. The trial evaluated whether supplementation increased faecal B. breve colonisation without adverse effects in 159 neonates. The authors conclude the strain is suitable for routine use in preterm infants, in the context of probiotic use for NEC prevention.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.